Kerry Powell
Acute Care · Pensacola, FLNPI 1477092211
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,449 of the $5,827 with a category attached, or 76.3%. 24 manufacturers reported payments, led by Livanova USA, Inc. at 26.7% of the total. Reporting peaked in 2022 at $2,102 and has fallen 54.5% since, to $956 in 2025. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $58.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Novartis$1K
- Argenx US, Inc.$775
- AbbVie$424
- Lundbeck LLC$322
- Amgen$248
- plus $1K from 18 others
What the payments were for
- Consulting fees$1503%
- Travel & lodging$1,21621%
- Food & beverage$4,44976%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 4 | $1,558 |
| Novartis | 25 | $1,108 |
| Argenx US, Inc. | 13 | $775 |
| AbbVie | 11 | $424 |
| Lundbeck LLC | 13 | $322 |
| Amgen | 4 | $248 |
| Biogen | 2 | $200 |
| SK Life Science, Inc. | 3 | $164 |
| Genentech USA, Inc. | 4 | $164 |
| Boston Scientific | 1 | $102 |
| UCB, Inc. | 4 | $101 |
| Chiesi USA, Inc. | 2 | $93 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| Jazz Pharmaceuticals Inc. | 1 | $91 |
| Medtronic | 1 | $89 |
| Amneal Pharmaceuticals LLC | 2 | $87 |
| Johnson & Johnson | 2 | $55 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| CSL Behring | 1 | $27 |
| Averitas Pharma Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,447
- KESIMPTA$238
- TYSABRI$150
- AIMOVIG$124
- UBRELVY$124
- VYVGART$122
- VYVGART HYTRULO$120
- VNS - Sentiva$111
- GENERAL DBS$102
How this compares
$5,827 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 25 | $250,288 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 16 | $189,262 |
| CopaxoneGlatiramer Acetate | 25 | $144,676 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $115,038 |
| Aimovig AutoinjectorErenumab-Aooe | 111 | $89,034 |
| UbrelvyUbrogepant | 73 | $88,229 |
| Emgality PenGalcanezumab-Gnlm | 49 | $63,692 |
| Nurtec OdtRimegepant Sulfate | 36 | $37,206 |
| GlatopaGlatiramer Acetate | 17 | $33,564 |
| FycompaPerampanel | 12 | $20,458 |
| Lacosamide | 149 | $19,068 |
| XcopriCenobamate | 11 | $12,949 |
| Levetiracetam | 268 | $9,762 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $8,483 |
| Dalfampridine ErDalfampridine | 34 | $6,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $200 | $115,03812 claims |
| AbbVieUbrelvy | $424 | $88,22973 claims |
| SK Life Science, Inc.Xcopri | $164 | $12,94911 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $87 | $2,03322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Pensacola
- Nicole AdamsPensacola$9K
- Melisa WilsonOrlando$214K
- Amanda PeacockJacksonville$81K
- Katrina RileyTampa$66K
- Diane GrayLake Mary$49K
- Heather RamousSafety Harbor$38K
- Melanie WeresJacksonville$37K
- Jayne JaramilloJacksonville$27K
- Melissa HamiltonTampa$23K
- Kimberly GrantAltamonte Springs$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.